We evaluated the outcome of 29 patients (age 22-60 years), who received a CD34+selected related (n ¼ 16) or unrelated graft (n ¼ 13) with limited T-cell addback (TCAB) (median 5.9 Â 10 4 /kg) following full-intensity conditioning for haematological malignancies. In all, 16 patients (55%) had either advanced disease or previous transplants. The cumulative incidences of grade 2-4 acute GVHD were 15.4 and 19.2% and that for chronic extensive GVHD were 35 and 37% in related and unrelated graft recipients, respectively. The strongest predictor of nonrelapse mortality and overall survival was the absolute lymphocyte count (ALC) at 30 days; patients with ALCo0.35 Â 10 9 /l having an NRM and OS of 59.2 and 24.7%, compared to 10 and 90% in those with a higher ALC. Patients with acute leukaemia had poorer survival and this was associated with a lower ALC as well. Thus, TCAB with a CD34+ selected graft resulted in a comparable outcome in both older and younger patients, but the survival was strongly influenced by early lymphocyte recovery.
We evaluated the outcome of 29 patients (age 22-60 years), who received a CD34+selected related (n ¼ 16) or unrelated graft (n ¼ 13) with limited T-cell addback (TCAB) (median 5.9 Â 10 4 /kg) following full-intensity conditioning for haematological malignancies. In all, 16 patients (55%) had either advanced disease or previous transplants. The cumulative incidences of grade 2-4 acute GVHD were 15.4 and 19.2% and that for chronic extensive GVHD were 35 and 37% in related and unrelated graft recipients, respectively. The strongest predictor of nonrelapse mortality and overall survival was the absolute lymphocyte count (ALC) at 30 days; patients with ALCo0. 35 Â 10 9 /l having an NRM and OS of 59.2 and 24.7%, compared to 10 and 90% in those with a higher ALC. Patients with acute leukaemia had poorer survival and this was associated with a lower ALC as well. Thus, TCAB with a CD34+ selected graft resulted in a comparable outcome in both older and younger patients, but the survival was strongly influenced by early lymphocyte recovery. Bone Marrow Transplantation (2003) 32, 23-30. doi:10.1038/sj.bmt.1704082 Keywords: CD34+selection; T-cell addback; lymphocyte recovery Allogeneic SCT (allo-SCT) is often the only curative option for patients with relapsed or refractory acute leukaemias and other haematological malignancies. Despite the fact that the majority of such patients belong to the older age group, there is a reluctance to offer allo-SCT to older patients. The major reason for this is an increased mortality in older patients because of either regimen-related toxicities, infections or GVHD. 1, 2 The use of peripheral blood stem cell (PBSC) as the stem cell source results in faster engraftment and thus reduces early morbidity and mortality. [3] [4] [5] In addition, this has also facilitated durable engraftment following reduction in the intensity of conditioning. 6 Although reduced intensity conditioning (RIC) transplants have been successful in enabling the application of allo-SCT beyond the age barrier, GVHD has been a major complication following such transplants. 7, 8 Also, the curative potential of RIC transplants in advanced leukaemias is uncertain.
T-cell depletion (TCD) is the most effective method of preventing GVHD. [9] [10] [11] [12] However, this is generally associated with a higher incidence of rejection, relapse, poor immune reconstitution and consequent infections. [13] [14] [15] Despite these drawbacks, it might be argued that TCD might reduce TRM in the older individuals and allow allo-SCT to be extended beyond conventional age limits.
The optimal method of TCD remains debatable. The physical methods for TCD are demanding 9 and those based on monoclonal antibodies lack quantitative precision. 11, 12 The recent introduction of immunomagnetic selection technology to purify the desired population and the use of PBSC as graft source have allowed greater flexibility in processing of the graft. CD34+ cell selection by the Clinimacs procedure yields a very high-purity product with very low T-cell inoculum in the final product. 16 While this might be optimal for haplo-identical transplants, 17 this probably results in an increased incidence of serious infections in both related and unrelated transplants. 18 The number of T-cells in the graft, necessary to facilitate engraftment and yet not produce severe acute GVHD, remains to be defined in the clinical setting. We report our pilot experience with the use of CD34+ cell selection and limited T-cell addback (TCAB) in 29 patients transplanted for haematological malignancies.
Patients and methods
We evaluated 29 allograft recipients, who received a CD34+ selected related or unrelated graft with a TCAB, in the adult BMT unit at the Bristol Royal Hospital for Sick Children between April 1999 and April 2002. All were transplanted for haematological malignancies and the minimum duration of follow-up was 100 days (median 16 months, range 3-40 months). Informed consent was obtained from all patients.
Conditioning treatment
Conditioning regimens consisted of cyclophosphamide 60 mg/kg for 2 days (n ¼ 22) or etoposide 60 mg/kg single dose (n ¼ 5) and fractionated total body irradiation (TBI) at 1440 cGy in eight doses. Patients not receiving TBI received cyclophosphamide and busulfan 16 mg/kg over 4 days in four daily divided doses (n ¼ 2). All patients received intravenous Campath-1H at a dose of 0.2 mg/kg/ day from day À9 to À5 as an anti-rejection measure.
PBSC mobilistion and apheresis. All but two donors were fully matched for both HLA class I and class II by polymerase chain reaction (PCR)-SSP. Lenograstim (Chugai pharmaceuticals, UK), at a dose of 10 mg/kg, was subcutaneously administered to related donors for 4 days. The stem cell apheresis was carried out using Cobe Spectra continuous flow automated cell separator from day 5 onwards for a maximum of 3 days. The procedure was carried out using peripheral venous access and femoral catheters were used in donors with poor peripheral access.
CD34+selection and TCAB
Selection of CD34+ cells was carried out by the Clinimacs procedure (Miltenyi Biotech) and was performed as recommended by the manufacturers. In brief, PBSC collections were first washed in donor plasma using a Cobe 2991 cell processor (Gambro BCT) to remove excess platelets. Bone marrow harvests were volume-reduced to less than 200 ml using the Cobe Spectra (Gambro BCT) cell processor. Washed PBSC and volume-reduced bone marrow harvests were diluted 1 in 3 with Clinimacs Buffer (Miltenyi Biotech) before subsequent volume reduction and labelling with anti-CD34 Clinimacs reagent, as recommended by Miltenyi Biotech. Labelled cells were washed with Clinimacs buffer to remove excess antibody and the CD34+ cells isolated by immunomagnetic selection using the Clinimacs device.
Dose calculations for CD34+ and CD3+ cells were determined using cell counts obtained from a haematology analyser (Sysmex SE9500) and a 'lyse no wash', singleplatform flow cytometry method using flow count reference beads (Coulter). The flow cytometry method incorporated the ISHAGE gating strategy, 19 viability staining using 7-aminoactinomycin-D and an integral positive control. Samples from the initial harvests and all subsequent processing steps were tested to monitor the processing quality. A TCAB was prepared from a sample of the initial bone marrow or PBSC harvest or the negative fraction residue of the CD34 selection procedure. The calculated cell volume providing the CD3+ T-cell dose was either added directly to the selected CD34+ cells before infusion, or infused alongside the selected CD34+ cells.
GVHD prophylaxis
Patients received intravenous cyclosporin A at 3 mg/kg in two divided doses from day À1, until they were able to tolerate oral cyclosporine. In the absence of GVHD, oral cyclosporine was generally continued to day +180 posttransplantation with subsequent tapering. However, the duration of immunosuppression was modified according to the disease status at the time of transplant, with patients at a higher risk of relapse having early discontinuation of their immunosuppression. The dose of cyclosporin A was titrated to maintain plasma levels between 125 and 225 ng/l.
Post-transplant monitoring
Disease status was evaluated on bone marrow aspirate specimens at 1, 3 and 12 months on all patients, using morphological, cytogenetic and molecular markers, where applicable. Cytogenetic relapse was defined as the sustained presence of t(9:22) or other markers on two separate occasions, 4 weeks apart. Molecular relapse was defined as the demonstration of bcr-abl fusion mRNA transcripts or other relevant markers on two separate occasions, 4 weeks apart, in the absence of cytogenetic or haematological evidence of CML.
Supportive care
All patients were nursed in single rooms with highefficiency particulate air (HEPA) filters. Antimicrobial prophylaxis consisted of oral itraconazole suspension, ciprofloxacin and oral acyclovir from the beginning of conditioning treatment until 100 days post transplant. Oral cotrimoxazole was initiated when the neutrophil count was greater than 1.0 Â 10 9 /l. CMV surveillance. CMV sero-positive recipients or those receiving grafts from CMV sero-positive donors were defined as being at risk for CMV disease. CMV seronegative patients receiving grafts from CMV sero-negative donors were considered as low risk for CMV disease and these patients received CMV sero-negative blood products.
All CMV at-risk patients received intravenous acyclovir at 500 mg/m 2 thrice daily from day À1 to day +35, followed by oral acyclovir at 400 mg t.i.d. until day 100. The CMV at-risk patients were screened every week for CMV reactivation by non-nested PCR-based assay and pp65 antigenemia detection tests for 100 days post transplant or longer, if patients had GVHD. Patients received antiviral therapy with ganciclovir 5 mg/kg b.i.d., if two consecutive qualitative PCR assays were positive. CMV infection or reactivation was defined as PCR positivity on two consecutive assays, without clinical signs or symptoms. CMV disease was defined as demonstration of CMV by culture or early antigen detection tests in a bronchoalveolar lavage specimen in the presence of recent respiratory signs and symptoms with pulmonary infiltrates on radiology, or histological evidence of CMV from other visceral sites.
Definitions and statistical methods
Disease status was defined as advanced if acute leukaemia was beyond second remission (CR2) or refractory, CML was beyond first chronic phase (CP1), myeloma was beyond first plateau phase or poorly responsive to firstline therapy, MDS was subtype RAEB or RAEB-t (FAB) or if adverse cytogenetics were detected at diagnosis in patients in CR1. Patients were categorised as high-risk for an event (relapse or TRM), if they had advanced disease status or had relapsed after an autologous or allogeneic transplantation. Engraftment was defined as neutophil recovery to more than 0.5 Â 10 9 /l and platelet engraftment as unsupported platelet count of 20 Â 10 9 /l. Primary graft failure was defined as failure to engraft by day +28 and secondary graft failure as a decline in the neutrophil and platelet counts below 0.5 Â 10 9 and 20 Â 10 9 /l, respectively, after documentation of successful engraftment. Acute and chronic GVHD were defined according to standard criteria. 20, 21 Acute GVHD was evaluable in all patients beyond day 0 and chronic GVHD in survivors beyond 100 days. Nonrelapse mortality (NRM) was defined as death from any cause in patients in remission.
Univariate P-values and odds ratios were calculated from 2 Â 2 contingency tables using Fisher's exact modification, as necessary. Continuous variables were compared using Mann-Whitney's nonparametric method. Cumulative probabilities of engraftment, acute and chronic GVHD, relapse, overall survival (OS) and NRM were analysed by censoring for competing risk factors by the Kaplan-Meier method, and the difference between the groups was compared using log-rank w 2 -test. The KaplanMeier method was used for estimation of overall survival. The effect of the covariates (age, donor gender, risk status (standard vs high), CMV sero-status, graft composition (CD34+ cells) and graft TCAB) on the outcome variables were examined in an univariate model and the variables with P-value less than 0.10 were entered in the multivariate regression model.
Results

Patient characteristics
The patient characteristics are detailed in Tables 1 and 2 . The median age of the cohort was 40 years, with nine patients between 40 and 50 years of age and another six patients aged above 50 years. The majority (15/29) were transplanted for acute leukaemia or MDS. In all, 16 patients (55%) were considered to be at high risk of an event (relapse or nonrelapse death) because of advanced disease or previous transplant or both. In total, 13 patients received an unrelated donor graft and two of them were mismatched at a single HLA class I/II locus. Nine out of 13 unrelated donor graft recipients were at high risk compared to 7/16 sibling graft recipients (P ¼ 0.2). All related graft recipients received PBSC as stem cell source, compared to six out of 13 unrelated graft recipients (P ¼ 0.001).
Graft composition (Tables 1 and 2)
The median CD34+ cell recovery after the selection process was 67.7% and the median CD34+ cell count in the graft was 3.67 Â 10 6 (range 1.7-10.3). The TCAB to the graft was a median of 5.9 Â 10 4 /kg. Except for one patient, where a higher TCAB was planned (100 Â 10 4 /kg), the majority received a TCAB of 5 Â 10 4 /kg (range 4-40 Â 10 4 / kg). The targeted TCAB dose was achieved in all the patients. There was no difference in the graft composition between the donor types ( Table 2 ). The graft composition did not differ between age groups, but, as expected, the CD34+ cell dose was higher in the PBSC group (median 4.8 vs 2.2 in the BM group, P ¼ 0.01).
Engraftment (Table 3)
Neutrophil engraftment was prompt in both related and unrelated donor groups (median 13 days). Platelet engraftment occurred at a median of 29 days and was not related CD34+ selected graft and lymphocyte recovery S Chakrabarti et al to the donor type or stem cell source, but the rapidity of engraftment correlated with CD34+ cells in the graft (P ¼ 0.02).
One patient with secondary AML relapsed following a previous unrelated graft, failed to engraft and subsequently received a haploidentical graft. He succumbed to recurrence of leukaemia 6 months later. Another patient was transplanted for CML in chronic phase and he died of fungal pneumonia on day +24 and thus was not evaluable for primary graft failure.
Only one patient had a secondary graft failure on day +43, after successful engraftment on day +13. He was transplanted for CLL in third relapse and is currently alive and disease-free, having had autologous reconstitution. It is worth noting that all these three patients had received unrelated donor BM graft and the CD34+ cell doses were on the lower range for the cohort (1.78, 1.98 and 2.28 Â 10 6 / kg).
Graft-versus-host disease (Table 3) The cumulative probability of acute GVHD was 29.3% (11/29, 95% CI 11.3-48.3) and that of grade 2-4 acute GVHD was 16.9% (4/29, 95% CI 2-32). The probability of grade 2-4 GVHD was 15.4% (2/16, 95% CI 2-28.8) in the related and 19.4% (2/13, 95% CI 1-37.4) in the unrelated donor group (log rank P ¼ 0.8). Only two patients developed grade 3 GVHD and there was no mortality related to acute GVHD.
The cumulative probability of chronic GVHD was 56.2% (10/26, 95% CI 26.2-86.2). This was 40% (4/16, 95% CI 12-68) for related and 63% (5/10, 95% CI 33-100) for unrelated donor graft recipients (log rank P ¼ 0.47). The probability of extensive chronic GVHD was 35% (95% CI 1-79) for the former and 37% (95% CI 4-70) for the latter group (log rank P ¼ 0.7). There was no death directly attributable to chronic GVHD, but two patients succumbing to infectious pneumonia also had pulmonary GVHD ( Table 4) .
The occurrences of acute and chronic GVHD were not affected by the donor type, patient age, stem cell source, CD34+ cell dose or TCAB dose.
Infection (Table 3)
In all, 20 patients were at risk of CMV disease. CMV reactivation was documented in 13 patients and was not influenced by the donor type. However, only one patient developed CMV disease. Nonetheless, most patients experiencing reactivation of CMV required protracted and often repeated ganciclovir therapy for CMV reactivation (data not shown). There was no difference in the frequency of bacterial, fungal or non-CMV viral infections between related and unrelated donor groups ( Table 3 ). The incidence of any of these infections was not influenced by the CD34+ cell count, TCAB dose, donor type, patient age, stem cell source, high-risk status or GVHD.
Lymphocyte recovery (Figure 1)
The absolute lymphocyte count (ALC) at 30 and 100 days post transplant were a mean (7s.d.) of 0.35 Â 10 9 (70.25) and 0.71 Â 10 9 /l (70.51) respectively. There was no difference between the related and unrelated donor groups. Also, there was no influence of the graft composition (CD34+ cell dose and TCAB), patient age, source of stem cell and high-risk status on the lymphocyte recovery. However, there was a trend towards a lower lymphocyte count at 30 days, being associated with the occurrence of symptomatic infections (Figure 1 , P ¼ 0.07).
Relapse
The cumulative probability of relapse was 26.1% (5/29, 95% CI 6.1-46.1). Unrelated donor graft recipients had a 48.7% probability (4/13, 95% CI 14.4-83) of relapse Three of the five relapsed patients have succumbed to progressive disease. Of the two surviving patients, one patient with ALL is undergoing further chemotherapy. The other patient with CML had a cytogenetic relapse and is currently in molecular remission following DLI. The follow-up duration of the remainder of the patients transplanted for CML was short, varying between 3.8 and 16 months.
There was also a trend towards a correlation between the CD34+ cell count of the graft and relapse. The probability of relapse was 44% (4/13, 95% CI 11-77) in patients receiving grafts containing less than 3 Â 10 6 /kg CD34+ cells and 11.2% (1/16, 95% CI 0-31.2) in those receiving a higher CD34+ cell dose (P ¼ 0.09). In addition, relapse rate tended to be lower among patients with chronic GVHD (1/10, 12.5% probability, 95% CI 0-34.5), compared to those not developing chronic GVHD (4/16, 33.5% probability, 95% CI 8.5-59.5, P ¼ 0.18).
Nonrelapse mortality
The cumulative probability of NRM was 34.7% (8/29, 95% CI 14.6-54.8). This was similar in related and unrelated donor recipients (21.5%, 95% CI 1-42 and 46%, 95% CI 10-82, P ¼ 0.16). NRM was not increased in the older age group (4/14, 34.6%, 95% CI 4.6-64.6 in patients below 40 years and 4/15, 32.7%, 95% CI 4.7-60.7 in patients above 40 years). The causes of death are summarised in Table 4 . There was no impact of underlying disease, risk status, graft composition, CMV sero-status or GVHD on NRM.
There was no significant correlation between ALC as a continuous variable and NRM. However, when ALC was considered as a categorical variable with a cutoff value of 0.35 Â 10 9 /kg, which is the median ALC in this cohort at 30 days, there was a trend towards a higher NRM in patients with ALCo0.35 (6/16, 59 .2%, 95% CI 23-95.4), compared to those with higher ALC (2/13, 10%, 95% CI 0-28.4) (P ¼ 0.09, Figure 2 ).
Overall survival
The actuarial survival at 3 years was 49.1% (11/29, 95% CI 27-71.1). The survival for patients below 40 years was 43.6% (8/14, 95% CI 11.6-75.6) and that for those above 40 years was 56% (10/15, 95% CI 26.1-86.1) (P ¼ 0.4). The OS was not influenced by the risk status (9/16, 44.6%, 95% CI 16.6-72.6 in HR group and 9/13, 65.8%, 95% CI 27-71.1 in non-HR group, P ¼ 0.9). However, there was a trend towards better survival among related graft recipients (12/16, 67.3%, 95% CI 40.1-94.5), compared to those transplanted with unrelated grafts (6/13, 27.3%, 95% CI 0-57.2) (P ¼ 0.08).
The OS was related with the underlying disease. Patients transplanted for acute leukaemia had a 12.2% probability of survival (6/15, 95% CI 0-32.2), compared to 85% (13/14, 95% CI 67-100) in those with CML or lymphoproliferative malignancies (P ¼ 0.02). There was also a strong relation between the ALC count at 30 days and the OS. The patients who died had a lower ALC at 30 days (0.270.18) than the survivors (0.3970.26) (P ¼ 0.06). When considered as a categorical variable, the probability of survival in those with ALC40.35 at 30 days was 90% (1/ 10, 95% CI 72-100), compared to 24.7 (8/14, 95% CI 0-52.7) in patients with lower ALC (P ¼ 0.03, Figure 3 ). In patients with acute leukaemia, there is only one survivor among patients with ALC o 0.35, compared to 4/5 patients with a higher ALC (P ¼ 0.06).
On multivariate analysis, an ALC of less than 0.35 at 30 days (OR 18.5, 95% CI 1.3-256, P ¼ 0.02) was the most significant risk factor for mortality, followed by a diagnosis of acute leukaemia (OR 5.8, 95% CI 1.1-33.2, P ¼ 0.04). CD34+ selected graft and lymphocyte recovery S Chakrabarti et al
Quality of life assessment
The parameters measured for the assessment of quality of life (QOL) were duration of hospitalisation, transfusion requirements and performance status at the time of last follow-up (Table 3 ). The median duration of hospitalisation was 31 days (range 17-105) and this was similar in both donor-type groups. However, patients with CMV reactivation had a significantly longer in-patient stay (42.3721.2 days) compared to patients not experiencing CMV reactivation (26.675.5 days) (P ¼ 0.05). CMV reactivation was also associated with a greater transfusion requirement (10.275.5 vs 6.372.7 red cell units, P ¼ 0.07 and 17.3713.9 vs 9.875.9 platelet units, P ¼ 0.1). Transfusion requirements did not differ between related and unrelated donor groups (Table 3) . Performance status was assessed in the patients who were alive at the last follow-up. The median Karnofsky score was 90 (range 70-100). This was again similar in related and unrelated donor groups (Table 3) .
Discussion
In the UK MRC AML 10 trial, allogeneic transplantation was associated with more deaths in remission in patients above the age of 35 years, despite a lower relapse risk, compared to the chemotherapy arm. 1 The major causes of NRM in this trial were GVHD and infection. TCD of the graft could reduce the incidence of GVHD-related mortality in older patients, but may have an adverse impact on rejection, relapse and infection. Scant data exist on the feasibility of such transplants in older patients. One study reported a survival of 66% in patients above 50 years using TCD grafts, which was comparable to that in the younger cohort. 22 We have explored the possibility of using TBIbased conventional conditioning across the age barrier with TCD grafts from both related and unrelated donors. TCD was carried out by CD34+ selection using the Clinimacs procedure. The high efficiency of this method reduces the T-cell numbers reliably. Previous studies have suggested that at least 1 Â 10 5 /kg T cells are probably required to initiate clinical GVHD in HLA-matched setting. 23 Hence, we decided to have a minimum of 5 Â 10 4 /kg CD3+ cells added to the graft.
Engraftment was prompt and durable in both related and unrelated donor transplant recipients. A recent study highlighted the problem of graft rejection in UD transplants. 24 This was not a problem in our study possibly because of the use of Campath-1H in the conditioning regimen. The incidences of acute GVHD and chronic extensive GVHD were low even in unrelated donor graft recipients and were not influenced by age of the recipient. The incidence of severe acute GVHD was substantially reduced, but the proportion of patients developing chronic GVHD was not different from that seen with unmanipulated grafts. 3 This was partly due to early withdrawal of cyclosporine A in patients with advanced disease. However, the QOL parameters in older patients were comparable with the younger patients and the surviving patients have maintained a reasonable performance status.
The most important factor influencing the outcome in this study was the early lymphocyte recovery. Lower ALC at 30 days was associated with a higher NRM and a poorer overall survival. The importance of lymphocyte recovery in the outcome of transplantation has been highlighted in several studies. Slower lymphocyte recovery has been associated with deaths from infections and RRT following allogeneic PBSC transplants. 25 Lymphocytopenia has been associated with both CMV disease 26 and adenovirus infections 27 and increased incidence of respiratory virus infections. 28 Various components of T-cell subsets have been studied and poor recovery of CD4+ T-cells have been most commonly correlated with an increase in infectionrelated mortality. 26, 29 On the other hand, the ALC, rather than the lymphocyte subsets, has been implicated in NRM. 25 Various thresholds of ALC at 30 days have been considered, but the absolute number is probably relative and would depend on the type of transplant, GVHD prophylaxis and the underlying condition.
The lymphocyte recovery has been reported to have a significant impact on relapse in acute leukaemias. 30, 31 Relapse was higher in our study in patients with acute leukaemias. However, the data on relapse should be interpreted with caution as the short follow-up is expected to skew obviously the relapse data in favour of CML and lymphoproliferative disorders. Despite that, there appears to be an impact of lower lymphocyte count on the survival of patients with acute leukaemia. This was due to both relapse and NRM, although the effect on individual outcome variables could not be analysed due to small sample size.
TCD transplants have been associated with a favourable outcome in AML in first remission. 9, 10, 32 It is worth noting that all the patients with acute leukaemia in this study had relapsed, failed induction with two courses of standard AML therapy or had unfavourable prognostic features. There is definite role for a GVL effect in curing advanced leukaemias 33, 34 and poor lymphocyte recovery following TCD is unlikely to have a favourable influence in this setting. To improve the outcome both in terms of NRM CD34+ selected graft and lymphocyte recovery S Chakrabarti et al and relapse, pre-emptive TCAB might be considered for patients with low ALC at the early post-transplant period. In contrast to acute leukaemias, which are less susceptible to donor lymphocyte infusion after relapse, CML and low-grade LPD would be more susceptible to the GVL effect of DLI if used earlier in the course of relapse and result in improved DFS. 35, 36 The follow-up duration for patients with LPD or CML in our study was short, which would underestimate the true relapse risk. In addition, half of these patients had developed chronic GVHD, which seemed to have a protective effect against relapse. G-CSF mobilisation of PBSC grafts have been shown to alter the Th1/Th2 ratio of the lymphocyte subsets in the direction of a lesser allogeneic effect. 37 While this might influence the pattern of GVHD seen after PBSC transplantation, its effect on the immune reconstitution and relapse rates is unclear, particularly after TCD transplants.
Another study that employed a very similar conditioning regimen including Campath-1H and used CD34+ selected grafts without any TCAB, reported a slow lymphocyte recovery and a very high (63.6%) NRM. 18 Six of the 11 patients in this study died because of infections. However, the overall incidence of infection-related deaths was less in our study (5/29) . While, the only difference between the regimen employed in the above-mentioned study and that of ours is TCAB with the graft and this could have accounted for lesser infections in our cohort, we did not find a correlation between CD3+ cell dose in the TCAB and GVHD, lymphocyte recovery or infection. This is in contrast with other studies that have explored the effect of CD3+ cell dose following CD34+ selected grafts on GVHD and engraftment. 38, 39 One reason for this could be a rather uniform TCAB performed in our study. The other possibility is that the direct correlation between TCAB and transplant outcome was blunted probably by the use of pretransplant Campath-1H. It has been shown that Campath-1H has a prolonged half-life and its use even at day À5 is likely to affect the lymphocytes infused with the graft. 40 More importantly, the prolonged persistence of Campath-1H, when used in vivo, would also impede the early lymphocyte recovery as seen in our cohort. The use of Campath-1H in vivo has been associated with an increased incidence of CMV, adenovirus and respiratory viruses following both conventional as well as RIC transplants. 27, 28, 41 In addition, most of these were found to correlate with slow immune reconstitution.
Campath-1H was used pretransplant as a proengraftment measure. The possible detrimental effect of Campath-1H in vivo used in combination with a CD34+ selected graft on NRM has been highlighted in an earlier study, where TCAB was not employed. In retrospect, addition of Campath-1H may not be essential for matched-sibling transplants if TBI is being employed as a part of the conditioning and a reasonable CD34+ cell dose could be achieved. Additional host immunosuppression, if necessary, can probably be achieved with fludarabine without any adverse effect on the graft or the immune reconstitution, due to its short terminal half-life. Furthermore, use of PBSC rather than bone marrow for TCD unrelated donor grafts might result in improved immune reconstitution. 42 These might augment the beneficial effect of TCAB used along with a CD34+ selected graft.
In summary, the outcome of older patients in this study even with high-risk features was encouraging. Modifications in the conditioning protocol with the use of fludarabine rather than Campath-1H, further exploration of higher TCAB dose according to the risk status and measures to improve immune reconstitution in the posttransplant period as judged by the early lymphocyte recovery with the use of graded TCAB might reduce the NRM and improve the outcome of patients with advanced leukaemias as well.
